The crosstalk between src and hippo/YAP signaling pathways in non-small cell lung cancer (NSCLC)

Ping Chih Hsu, Cheng Ta Yang, David M. Jablons, Liang You*


研究成果: 期刊稿件文獻綜述同行評審

37 引文 斯高帕斯(Scopus)


The advancement of new therapies, including targeted therapies and immunotherapies, has improved the survival of non-small-cell lung cancer (NSCLC) patients in the last decade. Some NSCLC patients still do not benefit from therapies or encounter progressive disease during the course of treatment because they have intrinsic resistance, acquired resistance, or lack a targetable driver mutation. More investigations on the molecular biology of NSCLC are needed to find useful biomarkers for current therapies and to develop novel therapeutic strategies. Src is a non-receptor tyrosine kinase protein that interacts with cell surface growth factor receptors and the intracellular signaling pathway to maintain cell survival tumorigenesis in NSCLC. The Yes-associated protein (YAP) is one of the main effectors of the Hippo pathway and has been identified as a promoter of drug resistance, cancer progression, and metastasis in NSCLC. Here, we review studies that have investigated the activation of YAP as mediated by Src kinases and demonstrate that Src regulates YAP through three main mechanisms: (1) direct phosphorylation; (2) the activation of pathways repressing Hippo kinases; and (3) Hippo-independent mechanisms. Further work should focus on the efficacy of Src inhibitors in inhibiting YAP activity in NSCLC. In addition, future efforts toward developing potentially reasonable combinations of therapy targeting the Src–YAP axis using other therapies, including targeted therapies and/or immunotherapies, are warranted.

出版狀態已出版 - 06 2020


Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.


深入研究「The crosstalk between src and hippo/YAP signaling pathways in non-small cell lung cancer (NSCLC)」主題。共同形成了獨特的指紋。